Neumora Therapeutics Inc (NMRA) News

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and...

Neumora Therapeutics to Participate in Upcoming Conferences in November

WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities